Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
about
Oncolytic virotherapy for human malignant mesothelioma: recent advancesAn oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.Oncolytic viruses: From bench to bedside with a focus on safety.Oncolysis by paramyxoviruses: preclinical and clinical studies.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.Gene therapy for malignant mesothelioma: current prospects and challenges.Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies.Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620).A catalogue of treatment and technologies for malignant pleural mesothelioma.Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.Novel oncolytic viral therapies in patients with thoracic malignancies.Bioluminescence imaging serves as a dynamic marker for guiding and assessing thermal treatment of cancer in a preclinical model.Oncolytic Viral Therapy for Mesothelioma.PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
P2860
Q26826590-FED381D5-57F7-4399-8EDE-94B596A10812Q34011349-F1BD98EB-A921-4C3E-AA4E-6B2EA9D32EC0Q34044071-04100505-4D61-4077-82B9-62F658C1730BQ35861933-38DA07F8-DB8C-4088-BEA7-3EE6D9BAB266Q35861936-AD138288-9B17-4060-83FE-1ED1FDA63600Q36308045-44294796-1A53-4496-936A-0DAF54F0C37BQ37990940-86FFE0AA-BF2B-4DE5-9627-522987FCC769Q38079969-5635CD41-DACB-464C-80C5-4593949C3FF2Q38259582-3283812F-A1D7-4AC5-A025-3A93D55B4217Q38599166-994013B2-44A5-4AC1-918C-E1079C641D4FQ38701351-B2C3E94C-0CA2-466A-BB6C-1103EBC95E84Q38760623-B7020542-F1E8-4595-96FC-011450351702Q38860227-546333A6-99BD-4EC4-866A-9D3801FAF3B2Q38886736-8D0BF1AD-5A1B-41C5-8A6F-CBA51487FC70Q39005715-61056B98-40A4-4CF6-86BF-8C4EC60636B0Q39067827-5BBE8E04-4B15-4F6D-85AD-0145CDD3DC6EQ39371077-BC28FC34-19D9-48F8-A727-457D6D3916D8Q40051845-F81B6D09-7AD6-4C65-8AC1-6D67D5CAB54CQ52674215-20AE84AD-0CE5-4ED2-B52C-0AA4EBB5C4A5
P2860
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Genetically engineered oncolyt ...... alignant pleural mesothelioma.
@ast
Genetically engineered oncolyt ...... alignant pleural mesothelioma.
@en
type
label
Genetically engineered oncolyt ...... alignant pleural mesothelioma.
@ast
Genetically engineered oncolyt ...... alignant pleural mesothelioma.
@en
prefLabel
Genetically engineered oncolyt ...... alignant pleural mesothelioma.
@ast
Genetically engineered oncolyt ...... alignant pleural mesothelioma.
@en
P2093
P2860
P1476
Genetically engineered oncolyt ...... alignant pleural mesothelioma.
@en
P2093
Dmitriy Zamarin
Gerd R Silberhumer
Inna S Serganova
Joyce Wong
Mithat Gönen
Peter Brader
Ronald Blasberg
Segundo Jaime Gonzalez
P2860
P304
P356
10.1158/1535-7163.MCT-10-0090
P577
2010-09-21T00:00:00Z